Grit Bio Closes Series A+ Round for its Cell Therapy Oncology Therapies
publication date: Jul 16, 2021
Grit Biotechnology, a two-year-old Shanghai cell therapy company, closed a Series A+ round to develop its Tumor Infiltrating Lymphocytes (TIL) therapies. Its leading program is GT101, a genetically unmodified TIL product that is currently being tested at a multi-centered clinical trial in China for solid malignancy indications. The round was led by GL Ventures, the VC arm of Hillhouse Group, with participation from Apricot Capital and Junshi Bio, as well as continued support from existing shareholders, Decheng Capital and Matrix Partners. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.